ONK Therapeutics
Business Services · Ireland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
An Coirneal Pier Rd Unit 1, Barna, Conna...Website
www.onktherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About ONK Therapeutics
ONK has an exclusive global patent license agreement with Australia's Walter and Eliza Hall Institute of Medical Research (WEHI) providing the company with rights to CISH knockout (KO) in the field of human NK cells for the treatment of cancer, irrespective of the NK cell source. CISH KO is a highly researched edit in NK cells for which the first US patent has since been granted to WEHI. ONK Therapeutics is headquartered in the med-tech hub of Galway, Ireland, with a wholly-owned US subsidiary, ONK Therapeutics, Inc. based at JLabs @ San Diego.Explore more
ONK Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ONK Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if ONK Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once ONK Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
ONK Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if ONK Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at ONK Therapeutics
Product Launch: Get notified when ONK Therapeutics launches new products
Click to see if ONK Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on ONK Therapeutics recently announced quarterly report
Recommended Actions
Find VP level buyers at ONK Therapeutics
Find 3 more new buyers
Company Profile Activity
Activity Insights
ONK Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ONK Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ONK Therapeutics.
ONK Therapeutics financials insights
Gather financial insights about ONK Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Unspecified
$8M
2022
Series A
$21.5M
ONK Therapeutics Tech Stack
A closer look at the technologies used by ONK Therapeutics
See more technologies
Most Recent Scoops
Event
Events, Sales, Logistics / Supply Chain, Field /Outside Sales, Field Marketing, Manufacturing Operations, Operations
Open Position
Open Position
Funding
Left Company
Executive Move
ONK Therapeutics News & Media
ONK Therapeutics Brings in US Financial Experience with the Appointment of Dr. Allan Reine as Independent Non-Executive Director
Allan Reine joins the Board as independent Non-Executive Director Brings significant experience as CFO of NASDAQ-listed biotechs, where he helped raise over $700 million Over 20 years in the biotechnology industry with relevant experiences as a biotech CFO, portfolio management, sell-side...ONK Therapeutics Announces $21.5M Series A Financing to Advance Pipeline of Next-Generation Optimally Engineered Off-the-Shelf NK Cell Therapies
GALWAY, Ireland & SAN DIEGO--(BUSINESS WIRE)--ONK Therapeutics, an innovative NK cell therapy platform company, today announced the closing of its $21.5 million Series A financing, led by current investors Acorn Bioventures and ALSHC, who were joined by Cormorant Asset Management. The financing will enable ONK to maintain its strong momentum as it advances pre-clinical programs through comprehensive IND-enabling studies, including in-vivo proof-of-concept models across multiple programs. ONK wiUSPTO Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies
GALWAY, Ireland & SAN DIEGO--(BUSINESS WIRE)-- #CARNK--ONK Therapeutics Ltd, an innovative NK cell therapy company, today announced that the US Patent and Trademark Office (USPTO) has granted its licensed patent that covers CISH knockout (KO) in NK cells, irrespective of the source of the NK cells, including, for example, human cord blood-derived and human induced pluripotent stem cell (iPSC)-derived cells (Patent No. 11104735). Earlier this year ONK entered into an exclusive global patent licenONK Therapeutics and Trinity College Dublin Collaborate in an Enterprise Ireland Funded Project to Optimize Metabolism of NK Cells for Improved Cancer Therapies
GALWAY, Ireland & SAN DIEGO, Calif.--(BUSINESS WIRE)--ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has been awarded an Innovation Partnership Programme (IPP) grant by Enterprise Ireland (EI) to fund collaborative research at Trinity College Dublin, Ireland, led by Dr. David Finlay to optimize the metabolism and engineering of NK cells for improved cancer therapies. Dr. Finlay, Associate Prof. in Immunometabolism in the Schools of Biochemi
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ONK Therapeutics
Sign Up For FreeTo access detailed company insights
ONK has an exclusive global patent license agreement with Australia's Walter and Eliza Hall Institute of Medical Research (WEHI) providing the company with rights to CISH knockout (KO) in the field of human NK cells for the treatment of cancer, irrespective of the NK cell source. CISH KO is a highly researched edit in NK cells for which the first U... Read More
